Full text not available from this repository.
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Affective Disorders and General Psychiatry Zurich East|
|DDC:||610 Medicine & health|
|Deposited On:||24 Jan 2011 21:09|
|Last Modified:||23 Nov 2012 14:44|
|Publisher:||Nature Publishing Group|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page